Last reviewed · How we verify

NCT04094493

Vit D Role in Post Thyroidectomy Hypocalcemia

Status unknown EARLY_PHASE1 Last updated 19 September 2019
What this trial tests

EARLY_PHASE1 trial testing vit D in Thyroid Diseases in 30 participants. Status unknown.

Timeline
1 October 2019
Primary endpoint
1 July 2020
30 September 2020

Quick facts

Lead sponsorAssiut University
PhaseEARLY_PHASE1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment30
Start date1 October 2019
Primary completion1 July 2020
Estimated completion30 September 2020
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 18 to 60, any sex, with Thyroid Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hypocalcemia after total thyroidectomy is usually transient but it is of main concern as it requires either prolonged stay in the hospital or readmission. During the first 24 hours bleeding is the main complication, but from the second day to six months, transient hypocalcemia is of main concern. Hypocalcemia can be evaluated symptomatically as well as from laboratory testing. Signs and symptoms of hypocalcemia include numbness, tingling, and carpopedal spasm. Preoperative vitamin D prevents postoperative transient hypocalcemia after thyroidectomy .

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of vit D

Trials testing the same drug.

Other recruiting trials for Thyroid Diseases

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04094493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing